Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Centogene NV's enterprise value is $76.07 Mil.
Centogene NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.07 Mil. Therefore, Centogene NV's EV-to-EBITDA for today is -3.61.
The historical rank and industry rank for Centogene NV's EV-to-EBITDA or its related term are showing as below:
CNTGF's EV-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 15.06 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Centogene NV's PE Ratio (TTM) for today is calculated as:
Centogene NV's share price for today is $0.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Centogene NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.378.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Centogene NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTGF vs ISPC, CHEK, FUNI: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Centogene NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centogene NV EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Centogene NV's EV-to-EBITDA falls into.
Centogene NV's current Enterprise Value is $76.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Centogene NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Centogene NV (CNTGF) has a EV-to-EBITDA of -3.61 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Centogene NV.
Is Centogene NV's EV-to-EBITDA too high?
Centogene NV's current EV-to-EBITDA is -3.61. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's EV-to-EBITDA compare to ISPC and CHEK?
Centogene NV's EV-to-EBITDA of -3.61 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EV-to-EBITDA is 15.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.06, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Centogene NV. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centogene NV's current EV-to-EBITDA is -3.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current EV-to-EBITDA of -3.61. The current EV-to-EBITDA is -3.61. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Centogene NV (CNTGF), the current EV-to-EBITDA is -3.61 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score
Get the complete analysis for CNTGF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTGF has been successfully added to your 
